Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.0015 AUD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:46 PM 07/26/15 All times are local (Market data is delayed by at least 15 minutes).

tyrian diagnostics ltd (TDX) Snapshot

Open
A$0.0015
Previous Close
A$0.0015
Day High
A$0.0015
Day Low
A$0.0015
52 Week High
08/22/14 - A$0.0020
52 Week Low
08/22/14 - A$0.0010
Market Cap
1.5M
Average Volume 10 Days
572.4K
EPS TTM
A$-0.0002
Shares Outstanding
1.0B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TYRIAN DIAGNOSTICS LTD (TDX)

Related News

No related news articles were found.

tyrian diagnostics ltd (TDX) Related Businessweek News

No Related Businessweek News Found

tyrian diagnostics ltd (TDX) Details

Tyrian Diagnostics Limited develops and commercializes proprietary biomarkers and technologies for the diagnosis of active tuberculosis in Australia. It offers DiagnostIQ that consists of a disposable plastic capsule to conduct tests; and a USB-driven reader to assess results. The company is headquartered in Sydney, Australia.

tyrian diagnostics ltd (TDX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

tyrian diagnostics ltd (TDX) Key Developments

Tyrian Diagnostics Ltd., Annual General Meeting, Oct 27, 2014

Tyrian Diagnostics Ltd., Annual General Meeting, Oct 27, 2014.

Tyrian Diagnostics Limited Announces Audited Earnings Results for the Year Ended June 30, 2014

Tyrian Diagnostics Limited announced audited earnings results for the year ended June 30, 2014. For the year, the company reported revenue from continuing operations of AUD 482,194 against AUD 39,619 a year ago. Profit before income tax was AUD 79,709 against loss before tax of 132,360 a year ago. Profit from continuing operations was AUD 79,709 against loss from continuing operations of AUD 132,360 a year ago. Profit attributable to members of the company was AUD 79,709 against loss attributable to members of the company of AUD 132,360 a year ago. Net cash outflow from operating activities was AUD 99,673 against AUD 157,090 a year ago.

Tyrian Diagnostics Ltd., Annual General Meeting, Oct 30, 2013

Tyrian Diagnostics Ltd., Annual General Meeting, Oct 30, 2013., at 12:00 AUS Eastern Standard Time. Location: Taylor Collison Limited, Level 10. Agenda: To receive and consider the company's Financial Report, the Director's Report and the Independent Auditor's Report in respect of the year ended June 30, 2013; to consider remuneration report; and to elect Mr. Roger Amos as director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TDX:AU A$0.00 AUD 0.00

TDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TDX.
View Industry Companies
 

Industry Analysis

TDX

Industry Average

Valuation TDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.9x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TYRIAN DIAGNOSTICS LTD, please visit www.tyriandx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.